- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
NKTR Market Currents
more »
-
May 2 Nektar Therapeutics (NKTR): Q1 EPS of -$0.36 misses by $0.03. Revenue of $17.9M (+58% Y/Y). (PR)
Comment![Earnings, Healthcare]
NKTR in Focus
more »
NKTR Related Articles
more »
NKTR News
more »
-
at MarketWatch.com (Feb 29, 2012)
-
at CNBC.com (Oct 4, 2011)
-
at CNBC.com (May 16, 2011)
-
at MarketWatch.com (Jan 19, 2011)
-
at MarketWatch.com (Dec 13, 2010)
NKTR Press Releases and Filings
more »
-
PR Newswire (May 2, 2012)
-
PR Newswire (Apr 25, 2012)
-
PR Newswire (Apr 10, 2012)
-
PR Newswire (Mar 28, 2012)
-
PR Newswire (Mar 20, 2012)
NKTR Latest Transcript
more »
-
Thu, Nov 4, 2010
NKTR Cramer
more »
-
Tue, Jan 23, 2007
-
Thu, Oct 5, 2006
-
Thu, Sep 28, 2006
NKTR Instablog posts
more »
NKTR vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Our current proprietary product pipeline is comprised of... More
